Month: September 2020

HHS letter to Eli Lilly in response to their 340B price restrictions. HHS Tells Lilly, Don’t assume we agree on your position about 340B. See

U.S. senators wrote to the U.S. Health and Human Services (HHS) to urge the U.S. Health Resources and Services Administration (HRSA) “to take immediate action

Lilly starts the trend to limit 340B pricing to contract pharmacies. Other drug manufacturers follow including Sanofi, Merck, AstraZeneca, United Therapeutics, Novartis, Novo Nordisk See